Meowzempic is here.
Experts estimate that more than half of the world’s pet cats are overweight — and now the flabby tabbies might soon have their own version of Ozempic.
Pet meds company OKAVA Pharmaceuticals has announced that the first clinical trial — dubbed MEOW-1 (ManagEment of OverWeight cats with OKV-119) — for a feline GLP-1 agonist drug was a success.
The first cat has been successfully dosed in MEOW-1 (ManagEment of OverWeight cats with OKV-119). dennisvdwater – stock.adobe.com
The pet-tailored GLP-1 has the potential to enhance quality of life, promote healthy aging and even become the “most impactful life-extending therapy” available for felines, according to a press release .
Beyond simply weight loss, the drug could be the solution for common metabolic feline illness

New York Post Lifestyle
ABC News
Associated Press US News
Cover Media
Raw Story